SIT 052
Alternative Names: SIT-052Latest Information Update: 08 Feb 2023
At a glance
- Originator Sitryx
- Class Antifibrotics; Senotherapeutics; Small molecules
- Mechanism of Action Metabolism-modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Idiopathic pulmonary fibrosis
Most Recent Events
- 17 Jan 2023 Early research in Idiopathic pulmonary fibrosis in United Kingdom (unspecified route), prior to January 2023 (Sitryx pipeline, January 2023)